4-Nov-2024
An old drug with new tricks
Medical University of South CarolinaPeer-Reviewed Publication
Despite the promise against cancer shown by the anti-malarial drug hydroxychloroquine, clinical trials have proved disappointing, partly because cancer cells develop resistance to the drug. MUSC Hollings Cancer Center researchers report in Cell Cycle that resistance to hydroxychloroquine occurs not by restoring cellular recycling, as had been expected, but by affecting the division, metabolism and export of cancer cells. These findings could inform new combination therapies with hydroxychloroquine, enhancing the drug’s effectiveness against cancer.
- Journal
- Cell Cycle
- Funder
- NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health